vs
雅培（CLB）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
雅培的季度营收约是RIGEL PHARMACEUTICALS INC的1.7倍（$121.8M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 4.2%，领先379.8%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -1.4%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -3.4%）
雅培是一家总部位于美国伊利诺伊州阿伯特公园的跨国医疗保健企业，在全球医疗健康领域开展业务，主营诊断产品、营养健康产品、医疗器械，同时在美国境外销售医药产品，是全球知名的医疗健康提供商。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
CLB vs RIGL — 直观对比
营收规模更大
CLB
是对方的1.7倍
$69.8M
营收增速更快
RIGL
高出22.6%
-1.4%
净利率更高
RIGL
高出379.8%
4.2%
两年增速更快
RIGL
近两年复合增速
-3.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $121.8M | $69.8M |
| 净利润 | $5.1M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 1.5% | 33.2% |
| 净利率 | 4.2% | 384.0% |
| 营收同比 | -1.4% | 21.2% |
| 净利润同比 | — | 1769.2% |
| 每股收益（稀释后） | $0.11 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLBRIGL
| Q1 26 | $121.8M | — | ||
| Q4 25 | $138.3M | $69.8M | ||
| Q3 25 | $134.5M | $69.5M | ||
| Q2 25 | $130.2M | $101.7M | ||
| Q1 25 | $123.6M | $53.3M | ||
| Q4 24 | $129.2M | $57.6M | ||
| Q3 24 | $134.4M | $55.3M | ||
| Q2 24 | $130.6M | $36.8M |
净利润CLBRIGL
| Q1 26 | $5.1M | — | ||
| Q4 25 | $4.9M | $268.1M | ||
| Q3 25 | $14.2M | $27.9M | ||
| Q2 25 | $10.6M | $59.6M | ||
| Q1 25 | $-154.0K | $11.4M | ||
| Q4 24 | $7.4M | $14.3M | ||
| Q3 24 | $11.7M | $12.4M | ||
| Q2 24 | $9.0M | $-1.0M |
毛利率CLBRIGL
| Q1 26 | — | — | ||
| Q4 25 | 20.8% | 91.5% | ||
| Q3 25 | 22.0% | 93.2% | ||
| Q2 25 | 20.3% | 95.6% | ||
| Q1 25 | 19.5% | 91.7% | ||
| Q4 24 | 17.8% | 89.9% | ||
| Q3 24 | 20.5% | 85.5% | ||
| Q2 24 | 21.2% | 92.4% |
营业利润率CLBRIGL
| Q1 26 | 1.5% | — | ||
| Q4 25 | 11.5% | 33.2% | ||
| Q3 25 | 15.6% | 40.9% | ||
| Q2 25 | 11.7% | 60.1% | ||
| Q1 25 | 3.6% | 23.9% | ||
| Q4 24 | 11.0% | 28.9% | ||
| Q3 24 | 14.7% | 25.4% | ||
| Q2 24 | 12.3% | 1.2% |
净利率CLBRIGL
| Q1 26 | 4.2% | — | ||
| Q4 25 | 3.6% | 384.0% | ||
| Q3 25 | 10.6% | 40.2% | ||
| Q2 25 | 8.2% | 58.6% | ||
| Q1 25 | -0.1% | 21.5% | ||
| Q4 24 | 5.7% | 24.9% | ||
| Q3 24 | 8.7% | 22.5% | ||
| Q2 24 | 6.9% | -2.8% |
每股收益（稀释后）CLBRIGL
| Q1 26 | $0.11 | — | ||
| Q4 25 | $0.11 | $14.11 | ||
| Q3 25 | $0.30 | $1.46 | ||
| Q2 25 | $0.22 | $3.28 | ||
| Q1 25 | $0.00 | $0.63 | ||
| Q4 24 | $0.15 | $0.82 | ||
| Q3 24 | $0.25 | $0.70 | ||
| Q2 24 | $0.19 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $22.8M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $275.1M | $391.5M |
| 总资产 | $587.7M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资CLBRIGL
| Q1 26 | $22.8M | — | ||
| Q4 25 | $22.7M | $155.0M | ||
| Q3 25 | $25.6M | $137.1M | ||
| Q2 25 | $31.2M | $108.4M | ||
| Q1 25 | $22.1M | $77.1M | ||
| Q4 24 | $19.2M | $77.3M | ||
| Q3 24 | $21.5M | $61.1M | ||
| Q2 24 | $17.7M | $49.1M |
总债务CLBRIGL
| Q1 26 | — | — | ||
| Q4 25 | $110.3M | $52.5M | ||
| Q3 25 | $114.1M | $60.0M | ||
| Q2 25 | $124.6M | $60.0M | ||
| Q1 25 | $124.4M | $60.0M | ||
| Q4 24 | $126.1M | $60.0M | ||
| Q3 24 | $139.9M | $60.0M | ||
| Q2 24 | $147.6M | $60.0M |
股东权益CLBRIGL
| Q1 26 | $275.1M | — | ||
| Q4 25 | $266.0M | $391.5M | ||
| Q3 25 | $271.3M | $117.6M | ||
| Q2 25 | $261.3M | $81.9M | ||
| Q1 25 | $253.4M | $18.6M | ||
| Q4 24 | $246.6M | $3.3M | ||
| Q3 24 | $250.7M | $-14.6M | ||
| Q2 24 | $240.3M | $-29.9M |
总资产CLBRIGL
| Q1 26 | $587.7M | — | ||
| Q4 25 | $584.0M | $513.6M | ||
| Q3 25 | $591.4M | $242.5M | ||
| Q2 25 | $602.1M | $206.7M | ||
| Q1 25 | $591.5M | $176.0M | ||
| Q4 24 | $585.1M | $164.0M | ||
| Q3 24 | $600.5M | $139.4M | ||
| Q2 24 | $597.8M | $128.4M |
负债/权益比CLBRIGL
| Q1 26 | — | — | ||
| Q4 25 | 0.41× | 0.13× | ||
| Q3 25 | 0.42× | 0.51× | ||
| Q2 25 | 0.48× | 0.73× | ||
| Q1 25 | 0.49× | 3.23× | ||
| Q4 24 | 0.51× | 18.25× | ||
| Q3 24 | 0.56× | — | ||
| Q2 24 | 0.61× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.0M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $517.0K | — |
| 自由现金流率自由现金流/营收 | 0.4% | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 0.77× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $22.5M | — |
8季度趋势，按日历期对齐
经营现金流CLBRIGL
| Q1 26 | $4.0M | — | ||
| Q4 25 | $7.9M | $22.0M | ||
| Q3 25 | $8.5M | $24.0M | ||
| Q2 25 | $13.9M | $30.5M | ||
| Q1 25 | $6.7M | $-893.0K | ||
| Q4 24 | $20.6M | $14.5M | ||
| Q3 24 | $13.1M | $21.7M | ||
| Q2 24 | $17.1M | $302.0K |
自由现金流CLBRIGL
| Q1 26 | $517.0K | — | ||
| Q4 25 | $5.0M | — | ||
| Q3 25 | $6.5M | — | ||
| Q2 25 | $10.4M | — | ||
| Q1 25 | $3.9M | — | ||
| Q4 24 | $17.4M | — | ||
| Q3 24 | $10.4M | — | ||
| Q2 24 | $14.3M | — |
自由现金流率CLBRIGL
| Q1 26 | 0.4% | — | ||
| Q4 25 | 3.6% | — | ||
| Q3 25 | 4.8% | — | ||
| Q2 25 | 8.0% | — | ||
| Q1 25 | 3.1% | — | ||
| Q4 24 | 13.4% | — | ||
| Q3 24 | 7.7% | — | ||
| Q2 24 | 10.9% | — |
资本支出强度CLBRIGL
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 2.7% | — | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.2% | — |
现金转化率CLBRIGL
| Q1 26 | 0.77× | — | ||
| Q4 25 | 1.61× | 0.08× | ||
| Q3 25 | 0.60× | 0.86× | ||
| Q2 25 | 1.31× | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | 2.78× | 1.01× | ||
| Q3 24 | 1.12× | 1.75× | ||
| Q2 24 | 1.90× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
